Starbucks Shares Down 3%; Co To Host Investor Day 2022 Today
https://event.on24.com/wcc/r/3897312/F58C6DC171BC69DB68DC57028CA5AEEC
Benzinga Cannabis Award Winners Announced At Chicago Conference, Check Out Full List
For the first time ever, the 15th edition of the Benzinga Cannabis Capital Conference, underway in Chicago September 13-14, presented a series of Benzinga Cannabis Awards.
Synthetic Biologics Announces Phase I Study To Evaluate The Safety, Tolerability, And Efficacy Of VCN-01 In Combination With Durvalumab In Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma Of The Head And Neck Was Presented At The ESMO Congre…
Key data and conclusions featured in the Poster Presentation include:
·
Safety: Treatment with VCN-01 had an acceptable safety profile when administered with durvalumab in the
Anixa Biosciences’ Ovarian Cancer CAR-T Therapy To Be Presented At The Rivkin Center & American Association Of Cancer Research 14th Biennial Ovarian Cancer Research Symposium
Anixa Biosciences, Inc. (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose
Gamida Cell Presents Data Demonstrating The Impact Of Transplantation With Omidubicel For Patients With Hematologic Malignancies At 2022 Cord Blood Connect Meeting
- Patients treated with omidubicel reported higher health-related quality of life scores during first-year post-transplant as compared to transplantation with umbilical cord blood (UCB)
- If approved, Omidubicel is
Adagene Announced Publication of Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients With Advanced Tumors
Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced the publication of data showing the best-in-class potential of ADG126, a masked, anti-CTLA-4 SAFEbody®.
Regeneron Pharmaceuticals Announced 63% Combined Pathologic Response Rate for Neoadjuvant Libtayo Monotherapy in Stage II to IV Resectable CSCC Per Primary Analysis of a Confirmatory Phase 2 Trial; Data Presented at ESMO
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive clinical data for an investigational regimen of PD-1 inhibitor Libtayo® (cemiplimab) as neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma (CSCC).
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
Findings from ancillary study of Phase 3 STAMPEDE trial reveal Decipher Prostate test is prognostic for clinical outcomes in men with high-risk non-metastatic and metastatic prostate cancer
Data support Veracyte's plan to expand test availability in the U.S. and offer test globally as an in vitro diagnostic
Merck Announced Five-Year Data for KEYTRUDA Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer
Five-year overall survival rate of 19.4% and 18.4% for KEYTRUDA plus chemotherapy in KEYNOTE-189 and KEYNOTE-407, respectively
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials